GLP-1 drugs linked to a rare sight-threatening eye condition

What just happened

Australia’s Therapeutic Goods Administration has issued a class-wide safety update for all GLP-1 receptor agonist medications, adding a warning about non-arteritic anterior ischaemic optic neuropathy — NAION — to the product information for semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), liraglutide (Saxenda), and dulaglutide (Trulicity). The update follows the identification of 36 Australian adverse event reports: 23 with semaglutide, 10 with tirzepatide, and 3 with liraglutide.

NAION is a vascular event affecting the optic nerve — painless, sudden, and in most cases permanent. There is no effective treatment once it occurs. The TGA describes it as a condition that “may result in permanent visual impairment, including blindness.” That framing — not hedged, not softened — signals the regulator is treating this as a genuine clinical concern, not a precautionary footnote.

For the many Australians now on GLP-1 medications, managing weight or blood glucose in consultation with their GP, this is worth reading carefully. Not because stopping is the right call — for most people it is not — but because knowing one symptom could make an irreversible difference.

Both-and

The risk is real — and in absolute terms, rare

The TGA estimates approximately 2–18 additional NAION cases per 100,000 GLP-1 users annually. That is a low absolute number. NAION already has a background incidence in the general population — the question is whether GLP-1 use adds meaningfully to that rate. The regulator concluded it does.

Thirty-six cases across three drugs is not large by pharmacovigilance standards. But when the outcome is irreversible vision loss, regulators apply a precautionary threshold lower than for reversible adverse events. Adding the warning to all four GLP-1 agents — including dulaglutide, where no confirmed Australian cases were identified — indicates the TGA is treating the pattern as a class-level signal requiring population-wide action, not just individual case review.

The mechanism is not yet established

The biological mechanism linking GLP-1 receptor agonism to NAION remains under investigation. Proposed pathways involve GLP-1’s potential effects on vascular autoregulation and perfusion of the optic disc — the small anatomical structure where the nerve exits the eye. If GLP-1 receptor agonists alter the haemodynamic regulation of optic disc vasculature, even transiently, a person with pre-existing anatomical vulnerability could be tipped into an ischaemic event. But this remains theoretical. The causal link has not been established. What the TGA has established is an association robust enough to warrant a class-wide label change and clinician notification.

Attribution is complicated by overlapping risk

The population most likely to be on GLP-1 medications is also the population with the highest background risk for NAION. People with type 2 diabetes, hypertension, sleep apnoea, and advancing age each carry independent risk of optic nerve vascular compromise. This creates genuine uncertainty: are the 36 cases attributable to the drugs, or are they partly explained by the underlying conditions that prompted prescribing? The TGA’s update does not resolve this. What it says is that the signal — across three drugs, with clear class clustering — exceeds what background rates would predict.

The drugs still have strong evidence behind them

The TGA update does not recommend stopping GLP-1 medications. Semaglutide and tirzepatide have cardiovascular outcome trial data establishing meaningful reductions in major adverse cardiovascular events in people with established disease. For weight management in people with obesity, the clinical evidence base is substantial. The safety communication asked GPs to advise patients to seek urgent ophthalmological assessment if sudden or partial vision loss occurs, and confirmed that annual eye screening for diabetic patients on GLP-1 treatment remains appropriate — already standard diabetes management practice. This is a change to the safety profile, not to the clinical case for prescribing.

Who carries additional risk

The TGA notes that individual anatomical features of the eye — specifically a small cup-to-disc ratio on fundoscopy — may increase NAION susceptibility. A prior NAION episode in one eye significantly raises risk for the fellow eye. Other risk amplifiers include poorly controlled blood pressure, untreated sleep apnoea, significant hypotensive episodes, and concurrent use of phosphodiesterase-5 inhibitors. For patients with those additional factors, the conversation at the next GP visit now includes a specific ocular risk discussion. That is not a reason to avoid prescribing — it is a reason to ensure both doctor and patient are using the same risk framework.

My two cents

If you are on a GLP-1 medication — Ozempic, Wegovy, Mounjaro, Saxenda — this is not a crisis communication. These medications are well-studied, and for most people the benefit-risk balance remains firmly in favour of continuing.

The one thing worth adding to your working knowledge: sudden, painless vision change in one eye — blurring that appears without cause, a dark patch in your visual field, loss of peripheral vision — is the symptom that warrants a same-day call to your clinic or presentation to an emergency department. Do not wait to see if it improves. NAION does not.

At your next appointment, it is worth asking your GP whether an eye check is due. For people with diabetes, that review should already be happening annually. For people on GLP-1 medications for other reasons, the conversation has now shifted slightly — and that shift is worth naming.

Verdict: yes — a rare but irreversible risk that every person on a GLP-1 medication should know one symptom for.

---

Sources cited

1. TGA issues GLP-1 RA class-wide safety update. newsGP, RACGP, 2026. https://www1.racgp.org.au/newsgp/clinical/tga-issues-glp-1-ra-class-wide-safety-update
2. Medicines safety updates and alerts. Therapeutic Goods Administration, Australian Government. https://www.tga.gov.au/news-and-resources/safety-alerts-and-recalls